Innate Pharma
Clinical trials sponsored by Innate Pharma, explained in plain language.
-
New antibody shows promise in slowing early myeloma
Disease control CompletedThis phase 2 trial tested an antibody drug called IPH2101 in 30 people with smoldering multiple myeloma, an early form of bone marrow cancer. The drug aims to boost the immune system to attack cancer cells. Researchers measured how well it controlled the disease and checked for s…
Phase: PHASE2 • Sponsor: Innate Pharma • Aim: Disease control
Last updated Jun 24, 2026 11:07 UTC
-
New antibody shows promise for rare blood cancers
Disease control CompletedThis phase 2 trial tested a drug called lacutamab (IPH4102) in 170 people with advanced T-cell lymphoma, including Sezary syndrome and mycosis fungoides. The drug targets a protein on cancer cells to help control the disease. Participants received the drug alone or with chemother…
Phase: PHASE2 • Sponsor: Innate Pharma • Aim: Disease control
Last updated Jun 23, 2026 11:58 UTC